Eganelisib
High-circulating Myeloid-derived Suppressor Cells (Part H)
Infinity Pharmaceuticals, Inc.Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the High-circulating Myeloid-derived Suppressor Cells (Part H) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Infinity Pharmaceuticals, Inc. | Phase 1 | CC |
Same molecule, other indications
Eganelisib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →